Impact of Rs657152 Gene Polymorphisms on Inflammatory Markers in COVID-19 Patients With Type 2 Diabetes Mellitus
,
Abstract
COVID-19 has significantly affected people with pre-existing conditions, particularly those suffering from type 2 diabetes mellitus (T2DM), as it increases the risk of complications and mortality. The dysregulated inflammatory response in T2DM patients is a critical factor contributing to severe disease progression in these individuals. Recent research suggests that genetic variations, such as Rs657152 polymorphisms, could influence inflammatory markers and immune responses in T2DM patients infected with COVID-19. Understanding this genetic relationship is crucial for improving treatment strategies and predicting outcomes in this high-risk group. The present was designed to evaluate the correlation of Rs657152 gene polymorphisms with inflammatory markers in COVID-19 patients with T2DM. This study enrolled 91 participants, including 31 healthy individuals, 30 COVID-19 patients with T2DM, and 30 non-diabetic COVID-19 patients. Inflammatory markers (CRP, IL-6, D-dimer, and ferritin) were measured, and Rs657152 polymorphisms were genotyped. Statistical analysis was conducted using SPSS version 23. COVID-19 patients with T2DM showed significantly higher BMI, greater severity of COVID-19, and increased levels of inflammatory markers compared to non-diabetic patients. A significant correlation was observed between the Rs657152 polymorphisms and elevated levels of IL-6, D-dimer, and ferritin in T2DM patients (P<0.05). The polymorphisms of the Rs657152 gene may exacerbate the inflammatory response in COVID-19 patients with T2DM, contributing to increased severity of the disease.
2. Kumar A, Singh R, Kaur J, Pandey S, Sharma V, Thakur L, et al. Wuhan to world: the COVID-19 pandemic. Front Cell Infect Microbiol 2021;11:596201.
3. Park SE. Epidemiology, virology, and clinical features of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2; Coronavirus Disease-19). Clin Exp Pediatr 2020;63:119-24.
4. Lange KW. Coronavirus disease 2019 (COVID-19) and global mental health. Global Health J 2021;5:31-6.
5. Kazakou P, Lambadiari V, Ikonomidis I, Kountouri A, Panagopoulos G, Athanasopoulos S, et al. Diabetes and COVID-19; a bidirectional interplay. Front Endocrinol (Lausanne) 2022;13:780663.
6. Corrao S, Pinelli K, Vacca M, Raspanti M, Argano C. Type 2 diabetes mellitus and COVID-19: a narrative review. Front Endocrinol (Lausanne) 2021;12:609470.
7. Sharma A, Rukmini MS, Manjrekar PA, Pawar NM, Sowndarya K. D-dimer level and inflammatory markers in COVID-19 patients with and without diabetes mellitus-A comparative study during the first wave of the pandemic. Biomedicine 2023;43:1759-64.
8. Akácsos-Szász OZ, Pál S, Nyulas KI, Nemes-Nagy E, Fárr AM, Dénes L, et al. Pathways of coagulopathy and inflammatory response in SARS-CoV-2 infection among type 2 diabetic patients. Int J Mol Sci 2023;24:4319.
9. D’Souza F, Buzzetti R, Pozzilli P. Diabetes, COVID‐19, and questions unsolved. Diabetes Metab Res Rev 2023;39:e3666.
10. Ng JW, Chong ET, Lee PC. An Updated Review on the Role of Single Nucleotide Polymorphisms in COVID-19 Disease Severity: A Global Aspect. Curr Pharm Biotechnol 2022;23:1596-611.
11. Mahmood ZS, Fadhil HY, Hussein TA, Ad'hiah AH. Severity of coronavirus disease 19: Profile of inflammatory markers and ACE (rs4646994) and ACE2 (rs2285666) gene polymorphisms in Iraqi patients. Meta gene 2022;31:101014.
12. Khalaf QA, Rasool KH, Naji EN. Evaluation of IL-6 and IL-17A gene polymorphisms in Iraqi patients infected with COVID-19 and type 2 diabetes mellitus. Hum Antibodies 2023;31:35-44.
13. Pojero F, Candore G, Caruso C, Di Bona D, Groneberg DA, Ligotti ME, et al. The role of immunogenetics in COVID-19. Int J Mol Sci 2021;22:2636.
14. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054-62.
15. Földi M, Farkas N, Kiss S, Zádori N, Váncsa S, Szakó L, et al. Obesity is a risk factor for developing critical condition in COVID‐19 patients: a systematic review and meta‐analysis. Obes Rev 2020;21:e13095.
16. Sattar N, Valabhji J. Obesity as a risk factor for severe COVID-19: summary of the best evidence and implications for health care. Curr Obes Rep 2021;10:282-9.
17. Petrilli CM, Jones SA, Yang J, Rajagopalan H, O’Donnell L, Chernyak Y, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ 2020;369:m1966.
18. Lighter J, Phillips M, Hochman S, Sterling S, Johnson D, Francois F, et al. Obesity in patients younger than 60 years is a risk factor for Covid-19 hospital admission. Clin Infect Dis 2020; 71:896-7.
19. Saengsiwaritt W, Jittikoon J, Chaikledkaew U, Udomsinprasert W. Genetic polymorphisms of ACE1, ACE2, and TMPRSS2 associated with COVID‐19 severity: A systematic review with meta‐analysis. Rev Med Virol 2022;32:e2323.
20. Bornstein SR, Rubino F, Khunti K, Mingrone G, Hopkins D, Birkenfeld AL, et al. Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes Endocrinol 2020;8:546-50.
21. Zhang Y, Geng X, Tan Y, Li Q, Xu C, Xu J, et al. New understanding of the damage of SARS-CoV-2 infection outside the respiratory system. Biomed Pharmacother 2020;127:110195.
22. Abdullaev S, Denisenko N, Temirbulatov II, Kachanova AA, Tuchkova S, Mikhaylenko EV, et al. The rs11385942 and rs657152 variants are not associated with COVID-19 severity and outcomes in patients treated with favipiravir and remdesivir. Acta Biomedica Scientifica 2024;8:23-30.
23. Biswas M. Prevalence of rs11385942 and rs657152 single nucleotide polymorphisms in the world population susceptible to severe COVID-19. Arch Immunol Res Ther 2022;1-4.
24. Balanovsky O, Petrushenko V, Mirzaev K, Abdullaev S, Gorin I, Chernevskiy D, et al. The variation of genome sites associated with severe COVID-19 across populations: the worldwide and national patterns. medRxiv 2020: 2020.11.
| Files | ||
| Issue | Vol 62 No 3 (2024) | |
| Section | Original Articles | |
| DOI | https://doi.org/10.18502/acta.v62i3.17114 | |
| Keywords | ||
| Rs657152 Gene polymorphisms Corona virus disease 2019 (COVID-19) Type 2 diabetes mellitus Inflammatory markers C-reactive protein (CRP) Interleukin-6 (IL-6) | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
